Abstract
ABSTRACT:: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple Phase 3 trials; TAF single agent is being studied in two Phase 3 trials in chronic hepatitis B patients. We report the results of an open-label, non-comparative switch study evaluating the efficacy and safety of E/C/F/TAF in HIV/HBV-coinfected adults. At 48 wee 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA
Original language | English (US) |
---|---|
Journal | Journal of Acquired Immune Deficiency Syndromes |
DOIs | |
State | Accepted/In press - May 11 2016 |
Externally published | Yes |
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)